# Remternetug PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/remternetug

> The next catalyst for remternetug, sponsored by ELI LILLY & Co (LLY), is its primary completion, April 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | remternetug |
| Codes | LY3372993 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Alzheimer's Disease](https://sec-api.dev/indications/alzheimer-s-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06653153 (A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06653153

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Alzheimer's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06653153 (A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06653153

## Same indication

- [GSK4527226](https://sec-api.dev/pdufa/gsk4527226) (GSK)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [NBI-1117567](https://sec-api.dev/pdufa/nbi-1117567) (NBIX)
- [VHB937](https://sec-api.dev/pdufa/vhb937) (NVS)
- [Xanomeline/trospium chloride](https://sec-api.dev/pdufa/xanomeline-trospium) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/remternetug.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Remternetug PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/remternetug

```bibtex
@misc{secapidev_pdufa_remternetug_20261116,
  title        = {Remternetug PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/remternetug}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_remternetug_20261116","title":"Remternetug PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/remternetug","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
